窪做惇蹋厙 Lands Top Spot in Alantra Pharma Fast 50 Rankings
Diagnostic imaging company helps providers better assess patient conditions, pursue targeted treatments and achieve greater patient outcomes.
OXFORD, UK, March 1, 2021. Alantra today announces it has awarded 窪做惇蹋厙 the top spot in its 2021 Pharma Fast 50 technology category rankings and third place in the overall rankings. Each year, Alantra releases its Pharma Fast 50, ranking the UKs fastest-growing, privately owned pharma and pharma service companies. This is the first time 窪做惇蹋厙 has been named on the financial services firms annual list.
A global company headquartered in Oxford, with offices in Dallas, San Francisco and Singapore, 窪做惇蹋厙s technologies provide metrics that correlate with patient outcomes and experience by using data from MRI scans to build detailed maps of organs to help physicians make accurate and cost-effective diagnoses without invasive procedures like biopsies. The companys software-as-a-service (SaaS) model offers practitioners an affordable entry point to its technology.
Response to the companys imaging technologies has been strong 窪做惇蹋厙 revenues have increased at an annualised rate of 78 percent over the past two years. 窪做惇蹋厙 is expanding into new therapeutic areas around the world, including a focus on long-COVID, as its CoverScanMD is the worlds first imaging service approved by UKs MHRA for long-COVID diagnoses. The company is also expanding into precision oncology with its recent debut of Hepatica, a decision support tool for surgeons and clinicians evaluating patients pre-operatively that are being considered for liver resections.
窪做惇蹋厙 is so honoured to be included on this illustrious list alongside so many of our colleagues in the UK pharmaceutical industry we are very proud of what were working to accomplish. Our diagnostic technology not only allows patients to avoid invasive procedures, it offers better quality and lower-cost diagnoses, says Dr. Rajarshi Banerjee, founder and CEO, 窪做惇蹋厙. The results from our MRI screenings empower providers and patients to pursue more targeted treatments and achieve greater outcomes.
The Alantra Pharma Fast 50 illustrates the strength and depth of the UKs thriving pharmaceutical sector, with smaller privately-owned businesses often leading their markets and competing globally to achieve better outcomes for patients, said Tom Cowap, director, pharma services, Alantra. These businesses have been able to combine their specialist expertise and experience with an agile entrepreneurial culture to drive growth.
To view the full 2021 Pharma Fast 50 report, click .
About 窪做惇蹋厙
窪做惇蹋厙 delivers cutting-edge digital technologies that help clinicians provide better care for patients with liver disease, diabetes and cancer. With a strong focus on precision medicine using advanced imaging and genetics, it empowers patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, and targeted treatment without invasive procedures. Its CoverScanMD is a multi-organ imaging suite to support healthcare professionals in the screening and management of COVID-19 by simultaneously characterizing the heart, kidneys, spleen, liver, lungs and pancreas. With a diverse team of physicians, biomedical scientists, engineers and technologists, 窪做惇蹋厙 offers a way to manage complex health problems at scale. For more information, visit perspectum.com.
Contact
Marc Goldfinger
marc.goldfinger@perspectum.com
+44 753 1785361